Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Progressive Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Progressive Corp trades at $212.5 (market cap $124.38B). The key difference: Progressive Corp is far larger — about 13.2× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Progressive Corp pays a 6.5% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | PGR | |
|---|---|---|
Market Cap | $9.39B | $124.38B |
Sector | Health | Financials |
52-Week High | $356.25 | $252.68 |
52-Week Low | $241.71 | $190.40 |
Enterprise Value | $9.14B | $132.59B |
Dividend Yield | — | 6.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Progressive (PGR) trades at $215.33, showing minimal daily change. The stock exhibits a bullish technical trend with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates robust revenue growth, rising from $49.6B in 2022 to $87.6B in 2025, with net income reaching $11.3B. Recent Q2 2026 earnings beat expectations at $4.85 EPS, though Q1 2026 slightly missed. The current P/E ratio of 10.8 suggests reasonable valuation relative to earnings strength.
The outlook for PGR remains positive with a consensus price target of $231.20, indicating potential upside. Key opportunities include expanding bundled insurance offerings and solid profitability metrics like 34.94% ROE. Risks involve competitive pressures in auto insurance and potential margin compression from growth investments. Analyst sentiment is mixed with 36.59% buy ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
